These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31275446)

  • 1. The Relationship between Plasma Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease.
    Wang X; Xu T; Mungun D; Zhou C; Zha Z; Lu M; Fen C; Guo Y
    Dis Markers; 2019; 2019():4528382. PubMed ID: 31275446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event.
    Grauen Larsen H; Yndigegn T; Marinkovic G; Grufman H; Mares R; Nilsson J; Goncalves I; Schiopu A
    Atherosclerosis; 2019 Aug; 287():16-23. PubMed ID: 31181415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients.
    Isoyama N; Machowska A; Qureshi AR; Yamamoto T; Anderstam B; Heimburger O; Barany P; Stenvinkel P; Lindholm B
    Perit Dial Int; 2016; 36(3):269-76. PubMed ID: 26493750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor for advanced glycation end products polymorphisms in coronary artery ectasia.
    Aslan EI; Ozkara G; Kilicarslan O; Ser OS; Bostan C; Yildiz A; Diren Borekcioglu A; Ozturk O; Kucukhuseyin O; Yilmaz Aydogan H
    Gene; 2024 Jul; 916():148450. PubMed ID: 38588932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of S100A12 and soluble receptor for advanced glycation end products on the occurrence of severe acute pancreatitis.
    Zhao B; Chen Y; Sun WW; Chen WW; Ma L; Yang ZT; Huang J; Chen EZ; Fei J; Mao EQ
    J Dig Dis; 2016 Jul; 17(7):475-82. PubMed ID: 27251034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging markers of inflammation and oxidative stress as potential predictors of coronary artery disease.
    Tsirebolos G; Tsoporis JN; Drosatos IA; Izhar S; Gkavogiannakis N; Sakadakis E; Triantafyllis AS; Parker TG; Rallidis LS; Rizos I
    Int J Cardiol; 2023 Apr; 376():127-133. PubMed ID: 36758863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Association between soluble receptor for advanced glycation end products (sRAGE) and coronary and cerebral atherosclerosis].
    Yang SH; Han XJ; Hu HY; Chen W; Yang CZ; Tian JP; Guo CX
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(39):3062-3067. PubMed ID: 31648447
    [No Abstract]   [Full Text] [Related]  

  • 9. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
    Melin EO; Dereke J; Hillman M
    Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation.
    Falcone C; Bozzini S; D'Angelo A; Matrone B; Colonna A; Benzi A; Paganini EM; Falcone R; Pelissero G
    Dis Markers; 2013; 35(3):135-40. PubMed ID: 24167358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
    Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study.
    Jabaudon M; Blondonnet R; Roszyk L; Pereira B; Guérin R; Perbet S; Cayot S; Bouvier D; Blanchon L; Sapin V; Constantin JM
    PLoS One; 2015; 10(8):e0135857. PubMed ID: 26274928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients.
    Jung ES; Chung W; Kim AJ; Ro H; Chang JH; Lee HH; Jung JY
    J Korean Med Sci; 2017 Jan; 32(1):54-59. PubMed ID: 27914132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease.
    Mahajan N; Malik N; Bahl A; Dhawan V
    Atherosclerosis; 2009 Dec; 207(2):597-602. PubMed ID: 19576587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.
    Nakashima A; Carrero JJ; Qureshi AR; Miyamoto T; Anderstam B; Bárány P; Heimbürger O; Stenvinkel P; Lindholm B
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2213-9. PubMed ID: 20847094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Receptor for Advanced Glycation End Products (Rage) and Its Ligands in Plasma and Infrainguinal Bypass Vein.
    Malmstedt J; Frebelius S; Lengquist M; Jörneskog G; Wang J; Swedenborg J
    Eur J Vasc Endovasc Surg; 2016 Apr; 51(4):579-86. PubMed ID: 26905625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Plasma sRAGE (Soluble Receptor for Advanced Glycation End Products) Is Associated With Slower Carotid Intima-Media Thickness Progression and Lower Risk for First-Time Coronary Events and Mortality.
    Grauen Larsen H; Marinkovic G; Nilsson PM; Nilsson J; Engström G; Melander O; Orho-Melander M; Schiopu A
    Arterioscler Thromb Vasc Biol; 2019 May; 39(5):925-933. PubMed ID: 30917679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings.
    Paradela-Dobarro B; Agra RM; Álvarez L; Varela-Román A; García-Acuña JM; González-Juanatey JR; Álvarez E; García-Seara FJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1050-1060. PubMed ID: 31371263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis.
    Chen YS; Yan W; Geczy CL; Brown MA; Thomas R
    Arthritis Res Ther; 2009; 11(2):R39. PubMed ID: 19284577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease.
    Qi Y; Gong F; Zhang Q; Xie C; Wang W; Fu S
    Arthritis Res Ther; 2012 Nov; 14(6):R251. PubMed ID: 23171632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.